25C-NBOMe

From PsychonautWiki
(Redirected from 25c)
Jump to: navigation, search

Skull and crossbones darktextred2.png

25C-NBOMe can be fatal at heavy doses (as low as 4mg).[1]

It is strongly discouraged to take large amounts of this substance or to insufflate (snort) it. Please see this section for more details.

Summary sheet: 25C-NBOMe
25C-NBOMe
Molecular structure of 25C-NBOMe
25C-NBOMe.svg
Chemical Nomenclature
Common names 25C-NBOMe, Cimbi-36, 25C
Substitutive name 2C-C-NBOMe
Systematic name 2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.





Sublingual
Dosage
Threshold 50 - 100 µg
Light 100 - 300 µg
Common 300 - 700 µg
Strong 700 - 1000 µg
Heavy 25C-NBOMe can be fatal at heavy doses.[1]
Duration
Total 8 - 10 hours
Onset 0 - 15 minutes
Come up 30 - 90 minutes
Peak 4 - 6 hours
Offset 1 - 4 hours







DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

25C-NBOMe (also known as Cimbi-36, 2C-C-NBOMe, and "N-Bomb", although this term is used broadly to refer to the entire 25x-NBOMe family) is a novel synthetic psychedelic substance of the phenethylamine chemical class. It produces an array of visually-dominant and stimulating psychedelic effects when administered.

The name 25C-NBOMe, which short-hand for 2C-C-NBOMe, is a derivative of the phenethylamine psychedelic 2C-C. It was discovered in 2003 by Ralf Heim at the Free University of Berlin,[2] and subsequently investigated by a team at Purdue University led by David Nichols.[3] It has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET).[4][5]

It is worth noting that compounds of the NBOMe family are not orally active and should be administered sublingually by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes. 25C-NBOMe can also be vaporized and inhaled; this is known to cause significantly more rapid and powerful effects and a shorter duration. However, this route of administration is highly advised against due to the difficulties of measuring and handling substances that are both active in the microgram range as well as having a low therapeutic index.

This substance had no history of human use before being sold online as a designer drug in 2010.[citation needed] Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25C-NBOMe in humans, and it has been associated with many deaths and hospitalizations. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to approach this poorly understood psychedelic substance with the proper amount of precaution and harm reduction practices if choosing to use it.

Blotter paper containing 25C-NBOMe

Chemistry

25C-NBOMe or 2C-C-NBOMe is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as 2C-C. 25C-NBOMe is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as a chlorine atom attached to carbon R4. It differs from 2C-C structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group as shown in the image to the right. 25C-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family. This NBOMe addition contains a methoxy ether CH3O- bound to a benzene ring at R2.

Pharmacology

Further information: Serotonergic psychedelic

25C-NBOMe has efficacy at the 5-HT2A receptor where it acts as a potent partial agonist.[6] However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

In comparison to 2C-C, the addition of an NBOMe group to the structure results in a sixteen fold increase in potency, allowing even the most extreme of dosages to fit in liquid form onto tabs and blotter paper, which people often mistake for LSD.[7] In comparison to LSD however it is only a third of the potency.[8]

Subjective effects

The effects listed below are based upon the subjective effect index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects
Child.svg

Visual effects
Eye.svg

Cognitive effects
User.svg

Multi-sensory effects
Gears.svg

Transpersonal effects
Infinity4.svg

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

25C-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The LD50 has not yet been determined although it can be fatal at heavy dosages.[9] 25C-NBOMe overdoses have also been linked to multi-organ failure.[10][11]

It is advised that due to 25C-NBOMe's extreme potency it should not be insufflated (snorted) as this method of administration has been attributed to several fatal overdoses due to improper dosing.[12][9]

It is strongly recommended that one use harm reduction practices when using this substances.

Tolerance and addiction potential

25C-NBOMe is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 25C-NBOMe are built almost immediately after ingestion. After that, it takes about 7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). 25C-NBOMe presents cross-tolerance with all psychedelics, meaning that after the consumption of 25C-NBOMe all psychedelics will have a reduced effect.

Dangerous interactions

Ambulance2.png

This dangerous interactions section is a stub.

As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.

Although many substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be relatively harmless in low doses of each but can still increase the risk of unpredictable injury or death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Legality

  • Brazil - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[14]
  • Germany - Possession, production and sale is illegal.[15]
  • Sweden: 25C-NBOMe is classed as Schedule I.[16]
  • United Kingdom - 25C-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.[17]
  • Israel - The NBOMe series of psychoactives became controlled in Israel in May, 2013.[18]
  • New Zealand - 25C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.[19]
  • Russia - Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.[20][21]
  • United States - Several NBOMe series compounds will be temporarily scheduled in the United States for 2 years with the possibility of an additional year. The temporary scheduling applies to 25C-NBOMe, 25B-NBOMe, and 25I-NBOMe.[22]
  • China - As of October 2015 25C-NBOMe is a controlled substance in China.[23]
  • Latvia: 25C-NBOMe is a Schedule I controlled substance.[24]
  • Canada: 25C-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[25]

See also

External links

References

  1. 1.0 1.1 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
  2. Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.
  3. Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.
  4. https://www.ncbi.nlm.nih.gov/pubmed/21174090
  5. http://bitnest.ca/external.php?id=%2518%253A3%25172%251BE%2524K%255BG%2521%2524%257D%2504%2504V
  6. Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24397362
  7. 25C-NBOMe--new potent hallucinogenic substance identified on the drug market (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/22989597
  8. http://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_dose.shtml
  9. 9.0 9.1 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid - https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
  10. Fatal intoxication with the new designer drug 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/26324189
  11. Near fatal intoxication with the novel psychoactive substance 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24770890
  12. Near fatal intoxication with the novel psychoactive substance 25C-NBOMe (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/24770890
  13. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. https://doi.org/10.1007/BF03161089
  14. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  15. BtMG Anlage I | https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html
  16. Läkemedelsverkets författningssamling - http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf
  17. United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made
  18. https://www.erowid.org/chemicals/nbome/nbome_law.shtml
  19. ‘Legal high’ DIME not so legal | http://www.sciencemediacentre.co.nz/2012/03/13/legal-high-dime-not-so-legal/
  20. https://www.erowid.org/chemicals/nbome/nbome_law.shtml
  21. Постановление Правительства Российской Федерации от 6 октября 2011 г. N 822 г. Москва | http://www.rg.ru/2011/10/19/narko-dok.html
  22. DEA proposed rules | http://www.gpo.gov/fdsys/pkg/FR-2013-10-10/pdf/2013-24432.pdf
  23. 关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html
  24. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
  25. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28